Integra LifeSciences Holdings Corporation (NASDAQ:IART) issued an update on its FY17 earnings guidance on Wednesday morning. The company provided EPS guidance of $1.88-1.94 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.92. The company issued revenue guidance of $1.125-1.14 billion, compared to the consensus revenue estimate of $1.13 billion.
Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded up 0.63% during trading on Monday, reaching $49.39. The company’s stock had a trading volume of 37,006 shares. Integra LifeSciences Holdings Corporation has a 52 week low of $37.71 and a 52 week high of $56.42. The company has a 50 day moving average price of $53.52 and a 200 day moving average price of $46.63. The firm has a market capitalization of $3.86 billion, a P/E ratio of 60.23 and a beta of 0.73.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The company had revenue of $282.16 million for the quarter, compared to analysts’ expectations of $283.58 million. During the same quarter in the previous year, the firm posted $0.40 EPS. The firm’s quarterly revenue was up 13.2% on a year-over-year basis. On average, equities research analysts expect that Integra LifeSciences Holdings Corporation will post $1.90 EPS for the current fiscal year.
IART has been the topic of several recent analyst reports. Zacks Investment Research cut Integra LifeSciences Holdings Corporation from a hold rating to a sell rating in a research report on Wednesday, June 28th. Jefferies Group LLC boosted their target price on Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the stock a buy rating in a research report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $54.00 target price on Integra LifeSciences Holdings Corporation and gave the stock a buy rating in a research report on Monday, May 15th. Cantor Fitzgerald reiterated an overweight rating and set a $65.00 target price on shares of Integra LifeSciences Holdings Corporation in a research report on Monday, July 10th. Finally, ValuEngine lowered Integra LifeSciences Holdings Corporation from a buy rating to a hold rating in a research note on Tuesday, May 23rd. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $52.63.
In related news, Director Donald E. Morel, Jr. bought 2,500 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Thursday, August 3rd. The shares were purchased at an average price of $49.29 per share, with a total value of $123,225.00. Following the purchase, the director now owns 29,612 shares in the company, valued at $1,459,575.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Donald E. Morel, Jr. bought 10,000 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Friday, August 4th. The stock was bought at an average cost of $49.25 per share, for a total transaction of $492,500.00. Following the purchase, the director now owns 29,612 shares in the company, valued at approximately $1,458,391. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 17,550 shares of company stock worth $864,842. 21.50% of the stock is owned by corporate insiders.
WARNING: This piece was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://stocknewstimes.com/2017/08/07/integra-lifesciences-holdings-corporation-iart-issues-fy17-earnings-guidance-updated.html.
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
